Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 4/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
| ▸ | FLT4 | P35916 | 2/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | MARK3 | P27448 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | CLK2 | P49760 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15848818 | 0.80 | CLK1 (0.52) | CLK1MKNK2MAP4K4DYRK1ACCNC | |
| SCHEMBL13355052 | 0.80 | KIT (0.48) | CLK1KDRFGFR1GSK3BDYRK1A | |
| SCHEMBL5646211 | 0.79 | MAPKAPK2 (0.51) | CDK2KDRFLT1FLT4MKNK2 | |
| SCHEMBL12923974 | 0.79 | PIM1 (0.48) | CDK2KDRFGFR1FLT3CCNA2 | |
| SCHEMBL13354893 | 0.79 | BRD4 (0.53) | CLK1KDRFGFR1DYRK1ACLK4 | |
| SCHEMBL28432597 | 0.78 | MKNK1 (0.49) | KDRMKNK2FLT3CCNCCDK8 | |
| SCHEMBL844281 | 0.78 | LRRK2 (0.61) | KDRMKNK2CCNCCDK8MKNK1 | |
| SCHEMBL26027546 | 0.78 | CYP19A1 (0.49) | CCNCCDK8CYP19A1 | |
| SCHEMBL24921266 | 0.77 | CYP1A1 (0.52) | MKNK2FGFR1DYRK1AMKNK1 | |
| SCHEMBL13763422 | 0.77 | GAA (0.47) | CDK2KDRFLT1FLT4MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023006097-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER | 海创药业股份有限公司 | 2023-02-02 | — | — | WO | disclosed |
| US-8765735-B2 | Isoxazolines as inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8318735-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GILLESPIE PAUL | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122256-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators | GYS2, GYS1, GSK3A | CLK1 1353/4885CDK2 386/4885KDR 2548/4885 |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | CLK1 1048/4885CDK2 14/4885KDR 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.